masthead-publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Angiogenesis Apoptosis Autocrine Signaling Biology of neoplasia Biomarkers Bladder Breast Cancer CDKN2A mutation Cells Circulating miRNAs Colorectal cancer Comparison study Core Needle Biopsy Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes DLBCL Drug Response Efficacy EMT Epstein-Barr ERBB3 Esophageal Cancer Exosomes Extracellular Vesicles FFPE FGF Ligand Trap FGFR Gene Fusions Genetic Polymorphism Genitourinary cancer Head and Neck Cancer Heart HLA-E HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Checkpoint Inhibitors Immune Response Immuno-Oncology Immunotherapy Kidney Liposarcoma Liquid Biopsy Liver Lung Lupus Lymphoma Melanoma Mesothelioma Microenvironment miRNA Molecular Characterization Mouse mRNA custom Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets Oral Cancer Pancreas Pathway Analysis PBMCs PCA Cell Lines PIK3CA mutation Plasma Platform Comparison Programmed cell death protein 1 Prostate qNPA qPCR Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signatures Sinonasal Undifferentiated Carcinoma Squamous cell carcinoma Sub-typing Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Urothelial carcinoma VEGFR Xenograft Tissue

2020

Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis

Inaki, K., et al. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis. Abstract presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 June 22-24. Online Proceedings. Session PO.MCB09.01 Functional Genomics and Other Topics

Download pdf 1.1MB
View External Link

Comparison of HTG-edge targeted RNA sequencing platform with whole transcriptome RNA sequencing for clinical biomarker studies

O'Rourke, D., et al. Comparison of HTG-edge targeted RNA sequencing platform with whole transcriptome RNA sequencing for clinical biomarker studies. Abstract presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 June 22-24. Online Proceedings. Session PO.CL11.02 Predictive Biomarkers for Treatment Efficacy 1

Download pdf 249KB
View External Link

Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.

Moura, D. S., et al. Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study. J  Clin Oncol 38: 2020 (suppl; abstr 11546). DOI: 10.1200/JCO.2020.38.15_suppl.11546

Download jpg 6.0MB
View External Link

Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma

Xu, J., et al. Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma. J Clin Oncol 38: 2020 (suppl; abstr 3115). 

Download jpg 6.4MB
View External Link

Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).

Desai, J., et al. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr e15258). 

View External Link

Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome

Kim, E., et al. Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome. J Clin Oncol 38: 2020 (suppl; abstr e17506). DOI:10.1200/JCO.2020.38.15_suppl.e17506.

View External Link

Page last updated June 29, 2020